The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Organ preservation strategy using dostarlimab for dMMR/MSI-H resectable solid tumors with whole-genome–based MRD monitoring (D-CURE: EPOC2401).
 
Yuki Matsubara
Honoraria - Bristol Myers Squibb; MSD; Taiho Pharmaceutical
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Satoshi Yuki
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Ono Pharmaceutical; Roche; Taiho Pharmaceutical; Takeda
 
Michiaki Unno
Honoraria - AstraZeneca; Miyarisan pharmaceutical; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - Sonire Therapeutics
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst)
 
Naoki Takahashi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yu Sunakawa
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Merck; MSD K.K; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); ICON Clinical Research (Inst); IQvia (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Makoto Ueno
Honoraria - Amgen; Asca; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; Revolution Medicines; SERVIER; Taiho Pharmaceutical; Takeda; Viatris
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Revolution Medicines (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Kawakami
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly; Micin; MSD; Ono Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo
 
Takahiro Kojima
No Relationships to Disclose
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Taigo Kato
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Merck; MSD; Pfizer; Takeda
Research Funding - Takeda
 
Tomohiro Nishina
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Koji Ando
Honoraria - Merck
 
Shugo Yajima
No Relationships to Disclose
 
Qingjiang Hu
No Relationships to Disclose
 
Hiroshi Tanabe
No Relationships to Disclose
 
Shin Kobayashi
Honoraria - Merck KGaA; Ono Pharmaceutical
 
Masashi Wakabayashi
Honoraria - Kyowa Kirin Co., Ltd; Nihon Medi-Physics
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health